The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Secretary of Agriculture Brooke Rollins on Wednesday announced a plan to enhance the agency's ability to detect, control and ...

Deputy DA Andrew Wood ruled Eric Salisbury's fatal shooting of Manuel Garza was justified self-defense, releasing bodycam ...

Energy Stocks Have Had a Mixed Start to 2025. Natural Gas Is Hot and Oil Is Not. Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say Black boxes analyzed ...

Referring to the impact of artificial intelligence, Andy Jassy tells employees, "We expect that this will reduce our total corporate workforce." TikTok Ban Will be Delayed Another 90 Days by Trump An ...